Literature DB >> 6134565

Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

M J Dew, A D Harries, N Evans, B K Evans, J Rhodes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134565      PMCID: PMC1548114          DOI: 10.1136/bmj.287.6384.23

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  3 in total

1.  Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

Authors:  M J Dew; P Hughes; A D Harries; G Williams; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

2.  HA-966 effects on striatal dopamine metabolism: implications for dopamine compartmentalization.

Authors:  H J Broxterman; C F van Valkenburg; E L Noach
Journal:  J Pharm Pharmacol       Date:  1980-01       Impact factor: 3.765

3.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  3 in total
  34 in total

1.  Acute pancreatitis during oral 5-aminosalicylic acid therapy.

Authors:  M T Fiorentini; M Fracchia; G Galatola; A Barlotta; M de la Pierre
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

Review 2.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 3.  AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Cynthia W Ko; Siddharth Singh; Joseph D Feuerstein; Corinna Falck-Ytter; Yngve Falck-Ytter; Raymond K Cross
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 4.  Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis.

Authors:  E Adachi; K Okazaki; Y Matsushima; H Seno; K Uchida; H Nakase; C Kawanami; T Nakamura; T Chiba
Journal:  Int J Pancreatol       Date:  1999-06

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 6.  Inflammatory bowel disease in the elderly. Practical treatment guidelines.

Authors:  G A Akerkar; M A Peppercorn
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

7.  The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.

Authors:  I P Donald; S P Wilkinson
Journal:  Postgrad Med J       Date:  1985-12       Impact factor: 2.401

8.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

9.  Salicylate induced exacerbation of ulcerative colitis.

Authors:  T K Chakraborty; D Bhatia; R C Heading; M J Ford
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

10.  Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.

Authors:  H A Mardini; D C Lindsay; C M Deighton; C O Record
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.